Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)

Next Previous
Trial Profile

A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Dinutuximab (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications CNS cancer; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Glioma; Malignant melanoma; Medulloblastoma; Neuroblastoma; Osteosarcoma; Rhabdoid tumour; Rhabdomyosarcoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 04 Jul 2024 This study has been Completed in Belgium, According to European Clinical Trials Database record.
  • 04 Jul 2024 This study has been Completed in Belgium, According to European Clinical Trials Database record.
  • 19 Jun 2024 Planned End Date changed from 1 Oct 2028 to 1 Apr 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top